We believe this clinical result when added to the results from our in vitro and in vivo studies provides strong evidence to support identifying TNK2 as a novel target for personalized therapy for patients with basal-like/triple negative breast cancers that express high levels of this protein kinase. The gene discussed is TNK2; the disease is triple-negative breast carcinoma.